ATLANTA, July 29, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Macrogenics, Inc. (“MGNX” or the “Company”) (NASDAQ: MGNX). The lawsuit alleges that Defendants provided investors with material information concerning MGNX’s early interim safety data from MGNX’s ongoing TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo) in patients with metastatic astration – resistant prostate cancer (mCRPC) that materially mislead and/or failed to disclose information pertin ...